EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Daratumumab therapy in a pediatric case of C3 nephritic factor-positive proliferative glomerulonephritis with monoclonal IgG deposits

Sophia Giang iD, Anurag K Agrawal, Aris Oates

CEN Case Reports · 2024

DOI: 10.1007/s13730-024-00868-0 ↗

Kurz gefasst

Fallbericht in der Zeitschrift CEN Case Reports, 2024. Verfasst von Sophia Giang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of California, San Francisco, 550 16th Street, 4th Floor, Mailstop: 3214, San Francisco, CA, 94143, USA. sophia.…. Hauptthemen laut MEDLINE: Immunoglobulin G, Antibodies, Monoclonal, Glomerulonephritis, Membranoproliferative. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is an exceedingly rare cause of glomerulonephritis among children for which prognosis is generally poor, with low incidence of remission and high rates of recurrence after transplant. While there are more cases reported in the adult literature, substantial differences in pediatric vs. adult PGNMID render it essential that we further characterize pediatric cases to optimize management. We report the case of a 12-year-old male presenting initially with edema and hypertension who was subsequently diagnosed with IgG3/Kappa-dominant PGNMID. In the absence of any proven therapy and though without a detectable clone, he was empirically treated with daratumumab with positive effect to date. This is the first reported case of daratumumab monotherapy in pediatric PGNMID, as well as the first PGNMID case to detect presence of C3 nephritic factor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin GAntibodies, MonoclonalGlomerulonephritis, MembranoproliferativeHumansMaleChildComplement C3Treatment OutcomeGlomerulonephritis

Stichwörter der Autor:innen

C3 nephritic factorDaratumumabPediatric PGNMID

Substanzen

Immunoglobulin GAntibodies, MonoclonaldaratumumabComplement C3

Autor:innen und Institutionen

  • Department of Pediatrics, University of California, San Francisco, 550 16th Street, 4th Floor, Mailstop: 3214, San Francisco, CA, 94143, USA. sophia.giang@ucsf.edu.
  • Department of Pediatrics, University of California, San Francisco, 550 16th Street, 4th Floor, Mailstop: 3214, San Francisco, CA, 94143, USA.

ORCID-Profile: Sophia Giang

Zitieren

APA

Giang, S., Agrawal, A. K., & Oates, A. (2024). Daratumumab therapy in a pediatric case of C3 nephritic factor-positive proliferative glomerulonephritis with monoclonal IgG deposits. CEN Case Reports. https://doi.org/10.1007/s13730-024-00868-0

Vancouver

Giang S, Agrawal AK, Oates A. Daratumumab therapy in a pediatric case of C3 nephritic factor-positive proliferative glomerulonephritis with monoclonal IgG deposits. CEN Case Reports. 2024. doi:10.1007/s13730-024-00868-0

BibTeX
@article{Giang2024,
  author = {Giang, Sophia and Agrawal, Anurag K and Oates, Aris},
  title = {Daratumumab therapy in a pediatric case of C3 nephritic factor-positive proliferative glomerulonephritis with monoclonal IgG deposits},
  journal = {CEN Case Reports},
  year = {2024},
  doi = {10.1007/s13730-024-00868-0}
}
Kostenlos starten →